Clinical Trial Update: A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial of tinengotinib (TT-00420) in combination with standard treatments for prostate cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Tinengotinib (TT-00420) (tinengotinib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Prostate Cancer | Phase 1, Phase 2 | Status: RECRUITING